Limits...
Intratumoral androgen metabolism and actions in invasive lobular carcinoma of the breast.

Yoda T, McNamara KM, Miki Y, Takagi M, Rai Y, Ohi Y, Sagara Y, Tamaki K, Hirakawa H, Ishida T, Suzuki T, Ohuchi N, Sasano H - Cancer Sci. (2014)

Bottom Line: In ILC cases the status of 5αRed1 and 17βHSD5 was inversely correlated with tumor size (P = 0.0053) and nuclear grade (P = 0.0290), and significantly associated with better overall survival of the patients (P = 0.0059).These correlations suggest one protective mode of androgen action could be through modulation of estrogen metabolism.Results of our present study indicated that androgen-producing enzymes could play pivotal protective roles in AR-enriched ILC cases.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Tohoku University Graduate School of Medicine, Sendai.

Show MeSH

Related in: MedlinePlus

Status of 17╬▓-hydroxysteroid dehydrogenase type 2 (17╬▓HSD2) immunoreactivity was significantly higher in invasive lobular carcinoma (ILC) than in invasive ductal carcinoma (IDC) and inversely associated with tumor size in ILC cases. (a) 17╬▓HSD2 mRNA expression in four IDC and four ILC cases was analyzed using RT2 quantitative PCR. (b) Representive illustrations of 17╬▓HSD2 positive (left) and negative (right) cases in IDC (top) and ILC (bottom). 17╬▓HSD2 was localized in the cytoplasm of carcinoma cells. Scale bar = 100 ╬╝m. (c) 17╬▓HSD2 immunoreactivity in ILC and IDC specimens. (d) Correlation between 17╬▓HSD2 and androgenic enzymes in androgen receptor-positive ILC cases. (e) Tumor size was inversely correlated with 17╬▓HSD2 expression. Data of tumor size were available in a subset of breast cancer patients treated at Tohoku University Hospital or Tohoku Kosai Hospital. **P < 0.01. 17╬▓HSD5, 17╬▓-hydroxysteroid dehydrogenase type 5; 5╬▒Red1, 5╬▒-reductase type 1.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4462384&req=5

fig04: Status of 17╬▓-hydroxysteroid dehydrogenase type 2 (17╬▓HSD2) immunoreactivity was significantly higher in invasive lobular carcinoma (ILC) than in invasive ductal carcinoma (IDC) and inversely associated with tumor size in ILC cases. (a) 17╬▓HSD2 mRNA expression in four IDC and four ILC cases was analyzed using RT2 quantitative PCR. (b) Representive illustrations of 17╬▓HSD2 positive (left) and negative (right) cases in IDC (top) and ILC (bottom). 17╬▓HSD2 was localized in the cytoplasm of carcinoma cells. Scale bar = 100 ╬╝m. (c) 17╬▓HSD2 immunoreactivity in ILC and IDC specimens. (d) Correlation between 17╬▓HSD2 and androgenic enzymes in androgen receptor-positive ILC cases. (e) Tumor size was inversely correlated with 17╬▓HSD2 expression. Data of tumor size were available in a subset of breast cancer patients treated at Tohoku University Hospital or Tohoku Kosai Hospital. **P < 0.01. 17╬▓HSD5, 17╬▓-hydroxysteroid dehydrogenase type 5; 5╬▒Red1, 5╬▒-reductase type 1.

Mentions: It was previously reported that 17╬▓HSD2 reflected intratumoral androgenic actions in breast cancer.(27) In this study, 17╬▓HSD2 mRNA levels were quantified in the four ILC and four IDC cases summarized in Table 1 with RT2 qPCR, in order to compare 17╬▓HSD2 mRNA expression between ILC and IDC cases. As illustrated in Figure 4(a), the amount of 17╬▓HSD2 mRNA expression was 4.8-fold higher in ILC than IDC cases (P = 0.0775). The 17╬▓HSD2 immunoreactivity was also examined in order to further explore the significance of this particular enzyme with relation to androgen actions. Fifty-four IDC cases (Tohoku University Hospital) were selected so that ER, PR, Her2, Ki-67, stage, AR, 17╬▓HSD5, and 5╬▒Red1 status did not differ significantly with 46 ILC cases (Tohoku University Hospital). Immunoreactivity of 17╬▓HSD2 was detected in the cytoplasm of carcinoma cells (Fig. 4b). The number of 17╬▓HSD2-positive cases was significantly higher in ILC than in IDC despite nearly the same status of hormone receptors between ILC and IDC cases examined (Fig. 4c).


Intratumoral androgen metabolism and actions in invasive lobular carcinoma of the breast.

Yoda T, McNamara KM, Miki Y, Takagi M, Rai Y, Ohi Y, Sagara Y, Tamaki K, Hirakawa H, Ishida T, Suzuki T, Ohuchi N, Sasano H - Cancer Sci. (2014)

Status of 17╬▓-hydroxysteroid dehydrogenase type 2 (17╬▓HSD2) immunoreactivity was significantly higher in invasive lobular carcinoma (ILC) than in invasive ductal carcinoma (IDC) and inversely associated with tumor size in ILC cases. (a) 17╬▓HSD2 mRNA expression in four IDC and four ILC cases was analyzed using RT2 quantitative PCR. (b) Representive illustrations of 17╬▓HSD2 positive (left) and negative (right) cases in IDC (top) and ILC (bottom). 17╬▓HSD2 was localized in the cytoplasm of carcinoma cells. Scale bar = 100 ╬╝m. (c) 17╬▓HSD2 immunoreactivity in ILC and IDC specimens. (d) Correlation between 17╬▓HSD2 and androgenic enzymes in androgen receptor-positive ILC cases. (e) Tumor size was inversely correlated with 17╬▓HSD2 expression. Data of tumor size were available in a subset of breast cancer patients treated at Tohoku University Hospital or Tohoku Kosai Hospital. **P < 0.01. 17╬▓HSD5, 17╬▓-hydroxysteroid dehydrogenase type 5; 5╬▒Red1, 5╬▒-reductase type 1.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4462384&req=5

fig04: Status of 17╬▓-hydroxysteroid dehydrogenase type 2 (17╬▓HSD2) immunoreactivity was significantly higher in invasive lobular carcinoma (ILC) than in invasive ductal carcinoma (IDC) and inversely associated with tumor size in ILC cases. (a) 17╬▓HSD2 mRNA expression in four IDC and four ILC cases was analyzed using RT2 quantitative PCR. (b) Representive illustrations of 17╬▓HSD2 positive (left) and negative (right) cases in IDC (top) and ILC (bottom). 17╬▓HSD2 was localized in the cytoplasm of carcinoma cells. Scale bar = 100 ╬╝m. (c) 17╬▓HSD2 immunoreactivity in ILC and IDC specimens. (d) Correlation between 17╬▓HSD2 and androgenic enzymes in androgen receptor-positive ILC cases. (e) Tumor size was inversely correlated with 17╬▓HSD2 expression. Data of tumor size were available in a subset of breast cancer patients treated at Tohoku University Hospital or Tohoku Kosai Hospital. **P < 0.01. 17╬▓HSD5, 17╬▓-hydroxysteroid dehydrogenase type 5; 5╬▒Red1, 5╬▒-reductase type 1.
Mentions: It was previously reported that 17╬▓HSD2 reflected intratumoral androgenic actions in breast cancer.(27) In this study, 17╬▓HSD2 mRNA levels were quantified in the four ILC and four IDC cases summarized in Table 1 with RT2 qPCR, in order to compare 17╬▓HSD2 mRNA expression between ILC and IDC cases. As illustrated in Figure 4(a), the amount of 17╬▓HSD2 mRNA expression was 4.8-fold higher in ILC than IDC cases (P = 0.0775). The 17╬▓HSD2 immunoreactivity was also examined in order to further explore the significance of this particular enzyme with relation to androgen actions. Fifty-four IDC cases (Tohoku University Hospital) were selected so that ER, PR, Her2, Ki-67, stage, AR, 17╬▓HSD5, and 5╬▒Red1 status did not differ significantly with 46 ILC cases (Tohoku University Hospital). Immunoreactivity of 17╬▓HSD2 was detected in the cytoplasm of carcinoma cells (Fig. 4b). The number of 17╬▓HSD2-positive cases was significantly higher in ILC than in IDC despite nearly the same status of hormone receptors between ILC and IDC cases examined (Fig. 4c).

Bottom Line: In ILC cases the status of 5αRed1 and 17βHSD5 was inversely correlated with tumor size (P = 0.0053) and nuclear grade (P = 0.0290), and significantly associated with better overall survival of the patients (P = 0.0059).These correlations suggest one protective mode of androgen action could be through modulation of estrogen metabolism.Results of our present study indicated that androgen-producing enzymes could play pivotal protective roles in AR-enriched ILC cases.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Tohoku University Graduate School of Medicine, Sendai.

Show MeSH
Related in: MedlinePlus